SCHEMBL26033702

SCHEMBL26033702

Cn1cc(CCCN)nc(N2CCC(C(=O)OC#N)CC2)c1=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 9/20 0.39
ALDH1A1 P00352 8/20 0.39
KDM4E B2RXH2 7/20 0.39
MEN1 O00255 7/20 0.39
LMNA P02545 2/20 0.39
KDM1A O60341 1/20 0.38
SCD O00767 4/20 0.37
TDP1 Q9NUW8 2/20 0.35
MAPT P10636 9/20 0.35
L3MBTL1 Q9Y468 3/20 0.35
TSHR P16473 2/20 0.35
MAPK1 P28482 2/20 0.35
HSD17B10 Q99714 2/20 0.35
GAA P10253 2/20 0.35
HPGD P15428 2/20 0.35
CASP1 P29466 1/20 0.35
HTT P42858 1/20 0.35
NPSR1 Q6W5P4 4/20 0.35
HIF1A Q16665 3/20 0.34
NSD2 O96028 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26033644 0.79 SCD (0.42) KMT2AALDH1A1KDM4EMEN1LMNA
SCHEMBL21564611 0.72 LMNA (0.42) KMT2AALDH1A1KDM4EMEN1LMNA
SCHEMBL23257971 0.67 KMT2A (0.35) KMT2AALDH1A1KDM4EMEN1LMNA
SCHEMBL21564777 0.66 NEK2 (0.43) KDM4ELMNAHSD17B10HPGDHTT
SCHEMBL21564666 0.66 GAA (0.42) KMT2AALDH1A1MEN1L3MBTL1MAPK1
SCHEMBL21564779 0.65 KMT2A (0.39) KMT2AALDH1A1KDM4EMEN1LMNA
SCHEMBL21552933 0.64 OPRM1 (0.36) KMT2AALDH1A1KDM4EMEN1LMNA
SCHEMBL23258167 0.62 SYK (0.31)
SCHEMBL25295617 0.61 MAPT (0.54) KMT2AALDH1A1KDM4EMEN1LMNA
SCHEMBL31303109 0.61 MAPT (0.54) KMT2AALDH1A1KDM4EMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230250090-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES INC (US) 2023-08-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230250090-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE KDM1B, KDM1A, KDM2A KMT2A 17/4885ALDH1A1 839/4885KDM4E 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.